Access cutting-edge solid tumors treatment through this clinical trial at a research site in Bethesda. Study-provided care at no cost to qualified participants.
Access solid tumors specialists in Bethesda at no cost
This study follows strict safety protocols and ethical guidelines
All study-related solid tumors treatment provided free
The open label, first-in-human, phase 1, dose escalation component in refractory solid tumors has been completed. The Maximum Tolerated Dose and Recommended Phase 2 Dose (RP2D) was determined to be 1.5mg/kg. The Expansion Phase of this study is currently enrolling subjects with non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), cervical and uterine cancers who progressed on front line therapy. Subjects will be treated with NEO-201 at the RP2D (1.5 mg/kg) every 2
Sponsor: Precision Biologics, Inc
Check if you qualify for this solid tumors clinical trial in Bethesda, MD
If you're searching for solid tumors treatment options in Bethesda, MD, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Bethesda research site is actively enrolling participants for this clinical trial. You'll receive care from experienced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.